Eye prosthesis is the first to restore sight lost to macular degeneration

Stanford Medicine researchers, in collaboration with international partners and funded by Science Corp., have developed the PRIMA device, a wireless chip and high-tech glasses system that successfully restored functional vision in a clinical trial for patients with advanced age-related macular degeneration. The device, which replaces damaged photoreceptors and is the first eye prosthesis to provide 'form vision' beyond mere light sensitivity, enabled 27 out of 32 participants to regain reading ability, with some achieving 20/42 acuity. This breakthrough addresses a condition affecting over 5 million people globally and represents a significant advancement in treating incurable vision loss, with future iterations aiming for grayscale vision and higher resolution.

Analysis

The PRIMA device, developed by Stanford Medicine researchers and funded by Science Corp., represents a significant breakthrough in restoring functional vision for patients with advanced age-related macular degeneration (geographic atrophy). A clinical trial published in the New England Journal of Medicine reported that 27 out of 32 participants regained reading ability, with some achieving 20/42 visual acuity, marking the first eye prosthesis to provide "form vision" beyond mere light sensitivity. This innovation addresses a condition affecting over 5 million people globally.

The two-part device, comprising a wireless chip implanted in the eye and high-tech glasses, replaces damaged photoreceptors by converting images into electrical stimulation. Its unique design allows patients to merge natural peripheral vision with prosthetic central vision, offering a major advancement in treating irreversible blindness by leveraging preserved retinal neurons.

Future iterations aim to enhance the device's capabilities, including grayscale vision and higher-resolution chips with smaller pixels, potentially offering 20/80 vision and near 20/20 with electronic zoom. However, the trial noted side effects in 19 participants, such as ocular hypertension and retinal tears, though these were not life-threatening and mostly resolved within two months.

The required months-long training period for optimal performance highlights a practical consideration for patient adoption and rehabilitation. The development underscores the potential for Science Corp. (SCIE) in the medical device sector, particularly in addressing unmet needs in ophthalmology, given its foundational support for this technology.

Key Decisions for Investors

• Monitor Science Corp. (SCIE) for long-term growth potential given its funding role in this breakthrough technology, Evaluate the broader ophthalmology medical device market for potential M&A or partnership opportunities arising from this innovation, Track regulatory approval timelines, commercialization strategies, and further clinical data on long-term safety and efficacy of the PRIMA device.